Ponsegromab vs Visugromab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: GDF-15 · full Non-Small Cell Lung Cancer pipeline
Ponsegromab
Developed by Pfizer
NCT04299048 · Phase 1 · completed
Every participant in this small study received the same drug with no placebo or control group, so the reported adverse-event and laboratory-abnormality rates cannot be attributed to the drug versus the underlying advanced cancer and cachexia; all patients had an adverse event and roughly 40% had a serious adverse event, including one death.
Next expected readout: May 2028 · NCT07663630 (registry estimate)
Reported efficacy
Body weight change at week 12: Weight change at week 12: +2.02 kg (100mg), +3.00 kg (200mg), +5.37 kg (400mg) vs placebo -0.41 kg (all p<0.001) (met)
Result source: NCT05546476
Visugromab
Developed by CatalYm GmbH
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2029 · NCT07098988 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ponsegromab | Visugromab |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Ponsegromab
- —Not reported
- Visugromab
- —Not reported
OS, median
- Ponsegromab
- —Not reported
- Visugromab
- —Not reported
ORR
- Ponsegromab
- —Not reported
- Visugromab
- —Not reported
Duration of response, median
- Ponsegromab
- —Not reported
- Visugromab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Visugromab: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ponsegromab: 3 of 4 rows · Visugromab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ponsegromab |
|---|---|
| Dropout rate | 36.4%a NCT04299048 · Phase 1 · monotherapy show 2 more results—200mg Q3W NCT04803305 · Phase 1 · registry result, not featured evidence 25%200mg Q3W NCT04803305 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT04299048 · Phase 1 · monotherapy show 2 more results—200mg Q3W NCT04803305 · Phase 1 · registry result, not featured evidence —200mg Q3W NCT04803305 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 40%a NCT04299048 · Phase 1 · monotherapy show 2 more results25%200mg Q3W NCT04803305 · Phase 1 · registry result, not featured evidence 41.7%200mg Q3W NCT04803305 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 2 more results200mg Q3W urinary tract infection 25% (placebo 16.7%) anaemia 8.3% (placebo 0%) hypercalcaemia 8.3% (placebo 0%) NCT04803305 · Phase 1 · registry result, not featured evidence 200mg Q3W urinary tract infection 25% (placebo 16.7%) lethargy 16.7% (placebo 0%) nausea 16.7% (placebo 0%) NCT04803305 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ponsegromab
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponsegromab's landscape · Visugromab's landscape